Genotype Influences Mavacamten Responsiveness in Obstructive Hypertrophic Cardiomyopathy

Mavacamten is a cardiac myosin inhibitor that reduces left ventricular outflow tract (LVOT) gradient in patients with obstructive hypertrophic cardiomyopathy (oHCM), thereby potentially lessening the need for septal reductive therapy (SRT).1,2 However, the factors that govern mavacamten response remain poorly understood.